Matches in SemOpenAlex for { <https://semopenalex.org/work/W2262696150> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W2262696150 endingPage "183" @default.
- W2262696150 startingPage "176" @default.
- W2262696150 abstract "One hundred sixty-seven evaluable patients with non-small-cell lung cancer were randomized to receive high-dose cisplatin and vindesine (PVD), or cisplatin and VP-16-213 (etoposide epipodophyllotoxin) (PVP), or cisplatin with VP-16-213 and vindesine (PVPVD). The patient distribution and characteristics were similar in all the treatment arms. The response rate differences (35% in PVD arm, 30% in PVP arm, and 22% in PVPVD arm) were not statistically significant (P = .33). Response durations were 43 weeks in the PVD arm, 20 weeks in the PVP arm, and 27 weeks in the PVPVD arm. Median survival was 29 weeks in the PVD and PVP arms and 28 weeks in the PVPVD arm. Median survival time of responding patients was 76 weeks in the PVD arm and 65 weeks in the PVP arm; 78% of patients were alive at 22+ to 87+ weeks follow-up in the PVPVD arm. Myelosuppression was similar in all three treatment arms. Significantly more azotemia occurred in the PVD arm than in the PVP and PVPVD arms (P = .002), and significantly more neuropathy in the PVD and PVPVD arms than in the PVP arm (P = .003 and .005). All the treatment arms have similar antitumor activity in non-small-cell lung cancer, but the PVP combination is slightly less toxic than the PVD and PVPVD treatment arms." @default.
- W2262696150 created "2016-06-24" @default.
- W2262696150 creator A5004064839 @default.
- W2262696150 creator A5012851837 @default.
- W2262696150 creator A5032191916 @default.
- W2262696150 creator A5036061276 @default.
- W2262696150 creator A5048531550 @default.
- W2262696150 creator A5052894313 @default.
- W2262696150 creator A5062931781 @default.
- W2262696150 creator A5072786200 @default.
- W2262696150 date "1985-02-01" @default.
- W2262696150 modified "2023-09-25" @default.
- W2262696150 title "Randomized trial of three combinations of cisplatin with vindesine and/or VP-16-213 in the treatment of advanced non-small-cell lung cancer." @default.
- W2262696150 cites W1979300931 @default.
- W2262696150 cites W1995686464 @default.
- W2262696150 cites W1996285570 @default.
- W2262696150 cites W2018156001 @default.
- W2262696150 cites W2031072429 @default.
- W2262696150 cites W2040687309 @default.
- W2262696150 cites W2054387860 @default.
- W2262696150 cites W2059563719 @default.
- W2262696150 cites W2076205522 @default.
- W2262696150 cites W2120079339 @default.
- W2262696150 cites W2143594378 @default.
- W2262696150 cites W2256942795 @default.
- W2262696150 cites W2395935603 @default.
- W2262696150 cites W2408315716 @default.
- W2262696150 cites W249009951 @default.
- W2262696150 cites W3142144633 @default.
- W2262696150 doi "https://doi.org/10.1200/jco.1985.3.2.176" @default.
- W2262696150 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/2981982" @default.
- W2262696150 hasPublicationYear "1985" @default.
- W2262696150 type Work @default.
- W2262696150 sameAs 2262696150 @default.
- W2262696150 citedByCount "80" @default.
- W2262696150 countsByYear W22626961502012 @default.
- W2262696150 countsByYear W22626961502014 @default.
- W2262696150 crossrefType "journal-article" @default.
- W2262696150 hasAuthorship W2262696150A5004064839 @default.
- W2262696150 hasAuthorship W2262696150A5012851837 @default.
- W2262696150 hasAuthorship W2262696150A5032191916 @default.
- W2262696150 hasAuthorship W2262696150A5036061276 @default.
- W2262696150 hasAuthorship W2262696150A5048531550 @default.
- W2262696150 hasAuthorship W2262696150A5052894313 @default.
- W2262696150 hasAuthorship W2262696150A5062931781 @default.
- W2262696150 hasAuthorship W2262696150A5072786200 @default.
- W2262696150 hasConcept C126322002 @default.
- W2262696150 hasConcept C141071460 @default.
- W2262696150 hasConcept C168563851 @default.
- W2262696150 hasConcept C2776256026 @default.
- W2262696150 hasConcept C2776694085 @default.
- W2262696150 hasConcept C2776755627 @default.
- W2262696150 hasConcept C2778119113 @default.
- W2262696150 hasConcept C2778239845 @default.
- W2262696150 hasConcept C2779321808 @default.
- W2262696150 hasConcept C2779429289 @default.
- W2262696150 hasConcept C71924100 @default.
- W2262696150 hasConcept C90924648 @default.
- W2262696150 hasConceptScore W2262696150C126322002 @default.
- W2262696150 hasConceptScore W2262696150C141071460 @default.
- W2262696150 hasConceptScore W2262696150C168563851 @default.
- W2262696150 hasConceptScore W2262696150C2776256026 @default.
- W2262696150 hasConceptScore W2262696150C2776694085 @default.
- W2262696150 hasConceptScore W2262696150C2776755627 @default.
- W2262696150 hasConceptScore W2262696150C2778119113 @default.
- W2262696150 hasConceptScore W2262696150C2778239845 @default.
- W2262696150 hasConceptScore W2262696150C2779321808 @default.
- W2262696150 hasConceptScore W2262696150C2779429289 @default.
- W2262696150 hasConceptScore W2262696150C71924100 @default.
- W2262696150 hasConceptScore W2262696150C90924648 @default.
- W2262696150 hasIssue "2" @default.
- W2262696150 hasLocation W22626961501 @default.
- W2262696150 hasLocation W22626961502 @default.
- W2262696150 hasOpenAccess W2262696150 @default.
- W2262696150 hasPrimaryLocation W22626961501 @default.
- W2262696150 hasRelatedWork W2009235854 @default.
- W2262696150 hasRelatedWork W2037615430 @default.
- W2262696150 hasRelatedWork W2054932891 @default.
- W2262696150 hasRelatedWork W2085562186 @default.
- W2262696150 hasRelatedWork W2091003848 @default.
- W2262696150 hasRelatedWork W2414171948 @default.
- W2262696150 hasRelatedWork W2472543001 @default.
- W2262696150 hasRelatedWork W4252815737 @default.
- W2262696150 hasRelatedWork W4254355677 @default.
- W2262696150 hasRelatedWork W2093036068 @default.
- W2262696150 hasVolume "3" @default.
- W2262696150 isParatext "false" @default.
- W2262696150 isRetracted "false" @default.
- W2262696150 magId "2262696150" @default.
- W2262696150 workType "article" @default.